Moderate to Severe Acne - Pipeline Insight, 2024

Moderate to Severe Acne - Pipeline Insight, 2024

DelveInsight’s, “Moderate to Severe Acne - Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Moderate to Severe Acne pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Moderate to Severe Acne Understanding

Moderate to Severe Acne: Overview

Acne is a skin disease that's often misunderstood. Some people believe that it's contagious or is caused by dirt; both of these allegations are untrue. There are a number of factors, like stress, that can contribute to acne. Hormonal changes can contribute to acne, so women may be more susceptible during pregnancy and menopause. The severity of acne is determined by the scope and type of lesions. Moderate acne is characterized by inflammatory (papules, pustules, nodules) and noninflammatory (comedones) lesions. Severe acne consists of numerous or extensive papules and pustules, as well as many nodules/cysts. Moderate to severe acne, which often warrants a more aggressive treatment than mild acne, is usually approached with a combination of topical treatments and oral antibiotics.

""Moderate to Severe Acne - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Moderate to Severe Acne pipeline landscape is provided which includes the disease overview and Moderate to Severe Acne treatment guidelines. The assessment part of the report embraces, in depth Moderate to Severe Acne commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Moderate to Severe Acne collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Moderate to Severe Acne.
• In the coming years, the Moderate to Severe Acne market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies and academics that are working to assess challenges and seek opportunities that could influence Moderate to Severe Acne R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• A detailed portfolio of major pharma players who are involved in fueling the Moderate to Severe Acne treatment market. Several potential therapies for Moderate to Severe Acne are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Moderate to Severe Acne market size in the coming years.
• Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Moderate to Severe Acne) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Moderate to Severe Acne Emerging Drugs Chapters

This segment of the Moderate to Severe Acne report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Moderate to Severe Acne Emerging Drugs

• ASC40: Ascletis Pharma Inc.

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis. Human sebum production requires de novo lipogenesis, which is increased in acne and suppressed by the FASN inhibitor ASC40.

• BTX 1503: Botanix Pharmaceuticals

Botanix is developing BTX 1503, as a new treatment for moderate to severe acne, which targets multiple pathologies involved in the development of the disease and is delivered utilising Botanix’s proprietary Permetrex™ drug delivery technology.

Further product details are provided in the report……..

Moderate to Severe Acne: Therapeutic Assessment

This segment of the report provides insights about the different Moderate to Severe Acne drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Moderate to Severe Acne

There are approx. 10+ key companies which are developing the therapies for Moderate to Severe Acne. The companies which have their Moderate to Severe Acne drug candidates in the most advanced stage, i.e. phase II include, Ascletis Pharma Inc.

• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Moderate to Severe Acne pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
• Molecule Type

Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Moderate to Severe Acne: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Moderate to Severe Acne therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Moderate to Severe Acne drugs.

Moderate to Severe Acne Report Insights

• Moderate to Severe Acne Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Moderate to Severe Acne Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Moderate to Severe Acne drugs?
• How many Moderate to Severe Acne drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Moderate to Severe Acne?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Moderate to Severe Acne therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Moderate to Severe Acne and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Ascletis Pharma Inc.
• Botanix Pharmaceuticals
• Biofrontera Bioscience GmbH
• Novartis
• BIOPHARMX, INC.
• DERMATA THERAPEUTICS, INC
• AnaptysBio
• VYNE Therapeutics Inc.

Key Products

• ASC40
• BTX 1503
• BF-200 ALA
• LYS006
• BPX-01
• DMT310
• Imsidolimab
• FCD105